The ability to enhance immune responses to target cancer has revolutionised oncology, offering transformative clinical outcomes. However, a significant proportion of cancers remain unresponsive to immunotherapy, underscoring the need for strategies that deliver stronger immune activation. The challenge is that enhanced immunity to cancer is coupled to immune-related toxicities, mediated by T-cells attack on normal tissues due to failure of immune regulation. 

Addressing this challenge requires a systems-level understanding of how T-cells discriminate between self and non-self-antigens, and strategies to harness this knowledge to generate T-cells specific for cancer. 

This brand new EACR virtual conference will bring together leading basic and translational scientists to explore the mechanisms of T-cell antigen selectivity across multiple scales. By integrating insights from immunology, computational biology, and clinical research, the meeting aims to advance strategies for enhancing the cancer immunotherapeutic window by enhancing T-cell specificity.